Method AI Adds $20 Million to its Coffers

Method AI has raised $20 million in Series A funding led by a private family office with participation from Cleveland Clinic and JobsOhio Growth Capital Fund. The company plans to use the money to further develop its surgical ultrasound platform.

Method AI emerged from the Cleveland Clinic in 2021 to resolve surgical visualization challenges experienced by leading robotic surgeons. The firm’s technology visualizes anatomy that lies deep below the visible surface of an organ—anatomy that is beyond the view of current surgical camera systems. The platform will create a first-of-its-kind 3D subsurface map for physicians while providing them with real-time guidance against an AI-generated surgical plan. The company aims to significantly improve the cancer-free survival rate for patients, with the potential to reduce more than $1 billion in annual costs from the broader healthcare system.

“In complex oncology procedures, surgeons often have to remove tumors that are partially or completely embedded within the organ, making it extremely difficult to gauge the margins of the tumor during a live surgery,” Method AI Co-Founder/CEO Doug Teany said. “This incomplete view of the tumor and other critical anatomy leads to cancer left behind, unforeseen complications and loss of organ function. With the support of our investment partners, our technology can make the difference between completely removing a tumor or leaving part of it behind, which significantly impacts long-term patient outcomes.”

Despite advancements in robotic and minimally invasive procedures, up to 40% of surgeries fail to fully remove the cancer. Method AI is developing a surgical navigation platform that allows for continuous 3D ultrasound imaging throughout a procedure. Its real-time algorithms build a map of critical subsurface features and will leverage machine learning to generate plans that guide physicians to the best possible surgical outcome.

Method AI is a medical technology company pioneering image-guided surgical navigation to improve patient outcomes. Its platform leverages continuous, 3D ultrasound and artificial intelligence (AI)-generated surgical plans to guide robotic-assisted procedures. Based outside Boston, and led by a team with deep medical device expertise, Method AI is reimagining the field of view for surgeons during complex, life-saving procedures.

The Method AI platform is currently under development. It is not yet cleared for commercial distribution in any country.